Surrozen, Inc./DE Net Income (Loss) Available to Common Stockholders, Basic
Surrozen, Inc./DE (SRZN) reported Net Income (Loss) Available to Common Stockholders, Basic of $32.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-06
- Surrozen, Inc./DE net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was $32.04M, a 46.91% increase year-over-year.
- Surrozen, Inc./DE net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$71.64M.
- Surrozen, Inc./DE net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was $21.81M.
- Surrozen, Inc./DE net income (loss) available to common stockholders, basic for the quarter ending 2024-09-30 was -$1.43M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month |
|---|---|---|---|
| 2026-06-30 | $32.04M 10-Q · filed 2026-08-06 | -$77.33M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$71.64M 10-Q · filed 2025-11-07 | -$49.84M derived: sum of 2 quarters · filed 2026-08-06 | -$58.87M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $21.81M 10-Q · filed 2026-08-06 | $5.21M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | -$1.43M 10-Q · filed 2025-11-07 | -$26.70M derived: sum of 2 quarters · filed 2025-11-07 | -$35.52M 10-Q · filed 2025-11-07 |
| 2024-06-30 | -$25.26M 10-Q · filed 2025-08-08 | -$34.09M 10-Q · filed 2025-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |